High-Dose Chemotherapy plus Stem Cell Transplantation in Advanced Germ Cell Cancer: A Review

European Urology

Volumn 56, Issue 1, 2009, Pages 57-64

  Connolly, Roisin M ^a,b   McCaffrey, John A ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Germ cell cancer; High dose chemotherapy; Stem cell transplant; Testicular cancer

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; OXALIPLATIN; PACLITAXEL; THIOTEPA; VINBLASTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG MEGADOSE; DRUG TOLERABILITY; GERM CELL TUMOR; HUMAN; INFECTIOUS COMPLICATION; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NON SEMINOMATOUS GERMINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; SINGLE DRUG DOSE; SKIN TOXICITY; STEM CELL TRANSPLANTATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TESTICULAR NEOPLASMS; TREATMENT FAILURE;

EID: 67349171549     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.03.018     Document Type: Review

References (54)

1. Einhorn L.H. Testicular cancer: an oncological success story. Clin Cancer Res 3 (1997) 2630-2632
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics 2007. CA Cancer J Clin 57 (2007) 43-66
3. Bosl G.J., and Motzer R.J. Medical progress: testicular germ-cell cancer. N Engl J Med 337 (1997) 242-254
4. Williams S.D., Birch R., Einhorn L.H., et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316 (1987) 1435-1440
5. Kondagunta G.V., Bacik J., Bajorin D.F., et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 23 (2005) 9290-9294
6. International Germ Cell Cancer Collaborative Group (IGCCCG). The International Germ Cell Consensus Classification: a prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 15 (1997) 594-603
7. Saxman S.B., Finch D., Gronin R., and Einhorn L.H. Long-term follow up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favourable-prognosis germ-cell tumors: the Indiana University experience. J Clin Oncol 16 (1998) 702-706
8. De Wit R., Roberts J.T., Wilkinson P.M., et al. Equivalence of 3 or 4 cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good prognosis germ cell cancer: a randomized study of the European Organisation for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperation Group and the Medical Research Council. J Clin Oncol 19 (2001) 1629-1640
9. Nichols C.R., Williams S.D., Loehrer P.J., et al. Randomized study of cisplatin dose intensity in poor risk germ cell tumors: a South Eastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9 (1991) 1163-1172
10. Bower M., Newlands E.S., Holden L., et al. Treatment of men with metastatic non-seminomatous germ-cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 8 (1997) 477-483
11. De Wit R., Louwerens M., de Mulder P.H., et al. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer 83 (1999) 831-833
12. Schmoll H.J., and Beyer J. Prognostic factors in metastatic germ cell tumors. Semin Oncol 25 (1998) 174-185
13. Bensiger W., Singer J., Appelbaum F., et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 81 (1993) 3158-3163
14. Pettengel R., Morgenstern G.R., Woll P.J., et al. Peripheral blood progenitor cell transplantation in lymphoma and leukaemia using a single apheresis. Blood 82 (1993) 3770-3777
15. Houck W., Abonour R., Vance G., et al. Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem cell transplantation using high-dose etoposide. J Clin Oncol 22 (2004) 2155-2158
16. Wierecky J., Kollmannsberger C., Boehlke I., et al. Secondary leukemia after first line high-dose chemotherapy for patients with advanced germ cell cancer. J Cancer Res Clin Oncol 131 (2005) 255-260
17. Loehrer Sr. P.J., Gonin R., Nichols C.R., et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell cancer. J Clin Oncol 16 (1998) 2500-2504
18. McCaffrey J.A., Mazumdar M., Bajorin D., et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15 (1997) 2559-2563
19. Fossa S.D., Stenning S.P., and Gerl A. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80 (1999) 1392-1399
20. Beyer J., Stenning S., Gerl A., et al. High-dose versus conventional-dose chemotherapy as first salvage therapy in patients with non-seminomatous germ-cell tumours: a matched pair analysis. Ann Oncol 13 (2002) 599-605
21. Einhorn L.H., Williams S.D., Chamness A., et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357 (2007) 340-348
22. Chevreau C., Droz J.P., Pico J.L., et al. Early intensified chemotherapy with autologous bone marrow transplant in first line treatment of poor risk non-seminomatous germ-cell tumours. Preliminary results of a French randomized trial. Eur Urol 23 (1993) 213-218
23. Droz J.-P., Kramar A., Biron P., et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol 51 (2007) 739-748
24. Schmoll H.J., Kollmannsberger C., Metzner B., et al. Long-term results of first line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21 (2003) 4083-4091
25. Bokemeyer C., Kollmannsberger C., Melsner C., et al. First-line high dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ-cell tumours. a multivariate and matched-pair analysis. J Clin Oncol 17 (1999) 3450-3456
26. Rosti G., De Giorgi U., Wandt H., et al. First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumours: the experience of the European Bone Marrow Transplant Solid Tumours Working Party. Bone Marrow Transplant 34 (2004) 1033-1037
27. Motzer R.J., Mazumdar M., Gulati S.C., et al. Phase II trial of high dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85 (1993) 1828-1835
28. Motzer R.J., Mazumdar M., Bajorin D.F., et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15 (1997) 2546-2552
29. Motzer R.J., Nichols C.R., Margolin K.A., et al. Phase 3 randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoeitic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25 (2007) 247-256
30. Bajorin D.F., Sarosdy M.F., Pfister D.G., et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multi-institutional study. J Clin Oncol 11 (1993) 598-606
31. McCaffrey J.A., Mazumdar M., Bajorin D.F., et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15 (1997) 2559-2563
32. Loehrer P.J., Gonin R., Nichols C.R., et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16 (1998) 2500-2504
33. Kondagunta G.V., Bacik J., Donadio A., et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23 (2005) 6549-6555
34. Nichols C.R., Tricot G., Williams S.D., et al. Dose-intensive chemotherapy in refractory germ cell cancer-a phase 1/2 trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7 (1989) 932-939
35. Einhorn L.H. Salvage therapy for germ cell tumours. Semin Oncol 21 Suppl 7 (1994) 47-51
36. Motzer R.J., Mazumdar M., Sheinfeld J., et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18 (2000) 1173-1180
37. Norton L., and Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 70 (1986) 163-169
38. Motzer R.J., Bajorin D.F., Schwartz L.H., et al. Phase II trial of paclitaxel shows anti-tumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12 (1994) 2277-2283
39. Motzer R.J., Chou T.C., Schwartz L.H., et al. Paclitaxel in germ cell cancer. Semin Oncol 22 (1995) 12-15
40. Kondagunta G.V., Bacik J., Sheinfeld J., et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide in previously treated germ cell tumors. J Clin Oncol 25 (2007) 85-90
41. Rick O., Beyer J., Kingreen D., et al. High-dose chemotherapy in germ cell tumours: a large single centre experience. Eur J Cancer 34 (1998) 1883-1888
42. Motzer R.J., Mazumdar M., Bosl G.J., et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14 (1996) 1098-1105
43. Rick O., Bokemeyer C., Beyer J., et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19 (2001) 81-88
44. Siegert W., Beyer J., Strohscheer I., et al., The German Testicular Cancer Cooperative Study Group. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem cell transplant in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol 12 (1994) 1223-1231
45. Bhatia S., Abonour R., Porcu P., et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18 (2000) 3346-3351
46. Saxman S.B., Nichols C.R., and Einhorn L.H. Salvage chemotherapy in patients with extragonadal non-seminomatous germ-cell tumors: the Indiana University experience. J Clin Oncol 12 (1994) 1390-1393
47. Pico J.L., Rosti G., Kramar A., et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16 (2005) 1152-1159
48. Fizazi K., and Zelek L. Is 'one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. Ann Oncol 11 (2000) 133-149
49. Lorch A., Kollmannsberger C., Hartmann J.T., et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ-cell tumors: a prospective randomized multicentre trial of the German Testicular Cancer Study Group. J Clin Oncol 25 (2007) 2778-2784
50. Bokemeyer C., Gerl A., Schoffski P., et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17 (1999) 512-516
51. Einhorn L.H., Stender M.J., and Williams S.D. Phase 2 trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 17 (1999) 509-511
52. Hinton S., Catalano P., Einhorn L.H., et al. Phase 2 study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20 (2002) 1859-1863
53. Einhorn L., Brames M.J., Juliar B., et al. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 25 (2007) 513-516
54. Kollmannsberger C., Beyer J., Liersch R., et al. Combination chemotherapy with gemcitabine plus oxaliplatin patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 22 (2004) 108-114